Showing results (51-60 of 93) with videos related to
Sort By:
Pageof 10
Journal of Clinical Microbiology|September 6, 2003
Comparison between prototype hybrid capture 3 and hybrid capture 2 human papillomavirus DNA assays for detection of high-grade cervical intraepithelial neoplasia and cancerPhilip E Castle, Attila T Lorincz, David R Scott, et al.Health and Quality of Life Outcomes|June 14, 2012
EQ-5D™-derived utility values for different levels of migraine severity from a UK sample of migraineursMegan R Stafford, Asha Hareendran, Daisy S Ng-Mak, et al.Current Medical Research and Opinion|January 17, 2019
Cost-effectiveness of pembrolizumab in combination with chemotherapy versus chemotherapy and pembrolizumab monotherapy in the first-line treatment of squamous non-small-cell lung cancer in the USRalph P Insinga, David J Vanness, Josephine L Feliciano, et al.Asian Pacific Journal of Cancer Prevention : APJCP|November 8, 2008
The cost-effectiveness of a quadrivalent human papillomavirus vaccine in TaiwanErik J Dasbach, Ralph P Insinga, Yuh Cheng Yang, et al.Journal of Medical Economics|March 20, 2026
Cost-effectiveness of pembrolizumab plus chemotherapy vs cemiplimab plus chemotherapy for first-line metastatic non-small cell lung cancer: a US payer perspective using a matching-adjusted indirect comparisonDanmeng Huang, Ying Zhang, Riddhi A Babel, et al.Immunotherapy|November 19, 2019
Cost-effectiveness of pembrolizumab versus chemotherapy as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in the USAMin Huang, Gilberto de Lima Lopes, Ralph P Insinga, et al.Pharmacoeconomics|September 18, 2009
Incremental 1-year medical resource utilization and costs for patients with herpes zoster from a set of US health plansRonald R White, Greg Lenhart, Puneet K Singhal, et al.American Journal of Obstetrics and Gynecology|March 4, 2008
Impact of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine in a sexually active population of North American womenEliav Barr, Christine K Gause, Oliver M Bautista, et al.Cancer Causes & Control : CCC|March 16, 2004
Prostate cancer screening and mortality: a case-control study (United States)Sheila Weinmann, Kathryn Richert-Boe, Andrew G Glass, et al.Journal of the National Cancer Institute|July 27, 2007
Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor statusAndrew G Glass, James V Lacey, J Daniel Carreon, et al.Pageof 10